Eli Lilly and Company $LLY Shares Sold by Sanctuary Advisors LLC

Sanctuary Advisors LLC reduced its position in Eli Lilly and Company (NYSE:LLY) by 0.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 241,945 shares of the company’s stock after selling 2,189 shares during the period. Eli Lilly and Company makes up approximately 1.2% of Sanctuary Advisors LLC’s holdings, making the stock its 9th largest holding. Sanctuary Advisors LLC’s holdings in Eli Lilly and Company were worth $222,534,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of LLY. Spire Wealth Management lifted its stake in shares of Eli Lilly and Company by 2.2% during the fourth quarter. Spire Wealth Management now owns 27,719 shares of the company’s stock worth $29,789,000 after purchasing an additional 592 shares in the last quarter. Coldstream Capital Management Inc. grew its stake in shares of Eli Lilly and Company by 25.6% in the third quarter. Coldstream Capital Management Inc. now owns 42,418 shares of the company’s stock valued at $32,365,000 after buying an additional 8,659 shares in the last quarter. Farther Finance Advisors LLC raised its holdings in shares of Eli Lilly and Company by 30.8% during the 4th quarter. Farther Finance Advisors LLC now owns 31,145 shares of the company’s stock valued at $33,471,000 after buying an additional 7,338 shares during the period. Iams Wealth Management LLC purchased a new stake in shares of Eli Lilly and Company during the 4th quarter valued at about $754,000. Finally, Militia Capital Partners LP boosted its stake in shares of Eli Lilly and Company by 333.3% in the third quarter. Militia Capital Partners LP now owns 2,600 shares of the company’s stock valued at $1,984,000 after purchasing an additional 2,000 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on LLY. BMO Capital Markets reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research note on Monday, June 15th. Morgan Stanley upped their price objective on shares of Eli Lilly and Company from $1,344.00 to $1,347.00 and gave the company an “overweight” rating in a research report on Wednesday, July 8th. Cantor Fitzgerald lifted their target price on Eli Lilly and Company from $1,230.00 to $1,350.00 and gave the stock an “overweight” rating in a research report on Monday, July 6th. The Goldman Sachs Group reiterated a “buy” rating and issued a $1,283.00 price target on shares of Eli Lilly and Company in a research note on Friday, May 22nd. Finally, Guggenheim increased their price target on Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the company a “buy” rating in a report on Monday. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,271.93.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly won full FDA approval for selpercatinib in solid tumors, a regulatory win that could support future oncology revenue and reinforces the strength of Lilly’s pipeline. Eli Lilly Wins Full FDA Approval for Selpercatinib in Solid Tumors
• Positive Sentiment: Wall Street sentiment remains constructive, with Guggenheim raising its price target on Lilly and maintaining a buy rating, while other recent reports highlighted bullish analyst views and momentum around the company’s pipeline. Eli Lilly Stock in Focus as Company Presents New Kisunla Data at AAIC Following Wave of Analyst Upgrades
• Positive Sentiment: Investors are also focused on Lilly’s obesity franchise, with articles noting that its weight-loss drugs now account for a very large share of revenue, underscoring how central that growth engine remains for the stock. Here’s How Much Eli Lilly’s Weight-Loss Drugs Are Worth to Investors
• Neutral Sentiment: Lilly has been presenting new Kisunla data at the Alzheimer’s Association International Conference, which keeps attention on its dementia pipeline but does not yet appear to have delivered a clear market-moving surprise. Eli Lilly Stock in Focus as Company Presents New Kisunla Data at AAIC Following Wave of Analyst Upgrades
• Neutral Sentiment: Commentary on whether Lilly’s shares can climb much higher has added to trading interest, but this is largely market speculation rather than a new fundamental catalyst. Is Lilly Stock On Track To Hit $2,090?
• Negative Sentiment: Despite the positive pipeline and analyst backdrop, traders are reacting to signs of weakness in LLY shares versus the broader market, suggesting some profit-taking or rotation out of the name. Eli Lilly (LLY) Stock Dips While Market Gains: Key Facts
• Negative Sentiment: One article flagged a “disturbing trend” in the billion-dollar obesity-drug market as Lilly prepares to roll out its new weight-loss pill, hinting at rising scrutiny of competition and execution risk in its most important growth category. Is This Disturbing Trend Bad News for Eli Lilly in the Billion-Dollar Obesity Drug Market?

Eli Lilly and Company Trading Down 2.3%

NYSE:LLY opened at $1,154.27 on Wednesday. The company has a market cap of $1.09 trillion, a PE ratio of 41.00, a P/E/G ratio of 1.44 and a beta of 0.51. The business’s 50 day moving average is $1,106.93 and its two-hundred day moving average is $1,034.58. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,249.45.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.97 by $1.58. The firm had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same period last year, the business posted $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, analysts predict that Eli Lilly and Company will post 35.5 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 24.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.